Literature DB >> 6313405

Adriamycin causes up regulation of epidermal growth factor receptors in actively growing cells.

G Zuckier, T R Tritton.   

Abstract

We have demonstrated a drug-dependent increase in the capacity of HeLa and 3T3 cells, grown in the presence of lethal and sublethal concentrations of adriamycin, to bind epidermal growth factor (EGF). Scatchard analysis ascribes this effect to an increase in the number of binding sites, with little change in affinity. The time course of binding of 125I-EGF is unchanged by adriamycin treatment, in both 3T3 and HeLa cells, at both 0 and 37 degrees C. This increase appears gradually over 3 or 4 days' exposure to the drug and is reversible over a similar period. Although in HeLa cells the increase reaches a maximum of about 4-fold, regardless of cell density, the maximum observed in 3T3 cells, over 100-fold, is seen only at low cell densities. This could be related to the density-dependent growth regulation seen in 3T3 cells, but not in HeLa cells. We suggest that the ability of the anticancer agent adriamycin to alter the cellular response to a growth-regulatory substance may be related to the mechanism of its cytotoxic action.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313405     DOI: 10.1016/0014-4827(83)90195-7

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Protein kinases and multidrug resistance.

Authors:  M G Rumsby; L Drew; J R Warr
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.

Authors:  H Depenbrock; A Shirvani; J Rastetter; A R Hanauske
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 3.  The epidermal growth factor receptor as a target for therapy in breast carcinoma.

Authors:  J Baselga; J Mendelsohn
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

Review 4.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

5.  Differential growth inhibition of isoquinolinesulfonamides H-8 and H-7 towards multidrug-resistant P388 murine leukaemia cells.

Authors:  M Ido; Y Nagao; M Higashigawa; T Shibata; K Taniguchi; M Hamazaki; M Sakurai
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

6.  Tumourigenic multidrug-resistant HT1080 cells do not overexpress receptors for epidermal growth factor.

Authors:  M L Slovak; S E Mirski; S P Cole; J H Gerlach; K H Yohem; J M Trent
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

7.  Twenty-seventh annual general meeting of the British Association for Cancer Research (in conjunction with the inaugural meeting of the Association of Cancer Physicians). March 24-26, 1986, Bristol, UK. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

8.  8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor.

Authors:  A Budillon; E Di Gennaro; M Caraglia; D Barbarulo; A Abbruzzese; P Tagliaferri
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.